| Autor: |
Yamada H; Department of Orthopaedic Surgery, Kyushu University, Fukuoka, Japan.; Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan.; Kondo Clinic of Rheumatology and Orthopaedic Surgery, Fukuoka, Japan., Tsuru T; PS Clinic, Fukuoka, Japan., Otsuka T; Munakata Medical Association Hospital, Fukuoka, Japan., Maekawa M; Maekawa Clinic of Rheumatology and Orthopedic Surgery, Fukuoka, Japan., Harada H; Morooka Orthopedic Clinic, Fukuoka, Japan., Fukuda T; Center for Rheumatic Diseases, Kurume University Medical Center, Kurume, Japan., Tsukamoto H; Department of Medicine and Biosystemic Science, Kyushu University, Fukuoka, Japan., Maeyama A; Department of Orthopaedic Surgery, Faculty of Medicine, Fukuoka University, Fukuoka, Japan., Yoshizawa S; National Hospital Organization Fukuoka Hospital, Fukuoka, Japan., Wada K; Wada Orthopaedic Clinic, Fukuoka, Japan., Nakashima Y; Department of Orthopaedic Surgery, Kyushu University, Fukuoka, Japan., Shono E; Shono Rheumatology Clinic, Fukuoka, Japan., Yoshizawa S; Hamanomachi Hospital, Fukuoka, Japan., Jojima H; Department of Orthopaedic Surgery, Fukuoka University Chikushi Hospital, Fukuoka, Japan., Kondo M; Kondo Clinic of Rheumatology and Orthopaedic Surgery, Fukuoka, Japan. |
| Abstrakt: |
Abatacept may exert its clinical effect on rheumatoid arthritis (RA) by suppressing anti-cyclic citrullinated peptide (CCP) antibody production. This study was undertaken to test this hypothesis by examining the changes of disease activity of RA and anti-CCP antibody levels over time after starting abatacept. Sixty Japanese RA patients who started abatacept were included in this multicenter, prospective observational study. Simple Disease Activity Index (SDAI) and anti-CCP antibody levels were evaluated at 12, 24, and 52 weeks. The mean SDAI score significantly decreased within 12 weeks after starting abatacept and was maintained thereafter. On the contrary, the mean anti-CCP antibody levels did not change until 52 weeks. At the individual level, there were substantial changes of anti-CCP antibody levels, but these were not correlated with the changes of disease activity at any time points. Thus, abatacept reduces the disease activity of RA independently of modulating anti-CCP antibody production. |
